A Phase I Study Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2018
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Trabectedin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 04 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.
- 27 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.